Renal Cancer - Results from #2160

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. March 16, 2021

Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma (RCC): Final results of cohorts A, G, H, and I of IVY Phase I study. March 16, 2021

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. March 15, 2021

Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma. March 15, 2021

Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma. March 12, 2021

18Fluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes. March 12, 2021

Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients. March 11, 2021

Identification and validation of a two-gene metabolic signature for survival prediction in patients with kidney renal clear cell carcinoma. March 11, 2021

Tivozanib Receives FDA Approval for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma March 10, 2021

Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. March 10, 2021

Does Reduced Renal Function Predispose to Cancer-specific Mortality from Renal Cell Carcinoma? March 10, 2021

Renal Cell Carcinoma Health Disparities in Stage and Mortality among American Indians/Alaska Natives and Hispanic Americans: Comparison of National Cancer Database and Arizona Cancer Registry Data. March 9, 2021

Comprehensive Molecular Characterization and Response to Therapy in FH-Deficient Renal Cell Carcinoma. March 9, 2021

Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC. March 9, 2021

Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis. March 8, 2021

A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Versus Pembrolizumab Plus Axitinib and Versus Avelumab Plus Axitinib in First-Line Treatment of Advanced Renal Cell Carcinoma. March 8, 2021

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. March 8, 2021

Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. March 5, 2021

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. March 5, 2021

Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. March 4, 2021

Page 109 of 457